Date: 2016-08-09
Type of information: Collaboration agreement
Compound: gene therapy treatments
Company: Abeona Therapeutics (USA - NY) EB Research Partnership (EBRP) (USA - NY) EB Research Medical Foundation (EBMRF) (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Dermatological diseases
Type agreement: collaboration
Action mechanism: gene therapy
Disease: epidermolysis bullosa
Details: * On August 9, 2016, Abeona Therapeutics, EB Research Partnership (EBRP) and EB Research Medical Foundation (EBMRF) announced a collaboration focusing on gene therapy treatments for epidermolysis bullosa. "The addition of the epidermolysis bullosa gene therapy programs to our clinical pipeline advances our mission of serving those impacted by rare disease. The strong Phase 1 clinical data demonstrate safety and initial efficacy one year post treatment, and support a follow-on Phase 2 trial for children suffering from epidermolysis bullosa," said Timothy Miller, PhD., President and CEO of Abeona Therapeutics. Phase 1 clinical trial results for the lead epidermolysis bullosa program, EB-101 for the treatment of recessive dystrophic epidermolysis bullosa, were recently presented at the opening Plenary Session of the Society for Investigative Dermatology in May 2016. Investigators at Stanford are recruiting patients for a Phase 2 trial to begin soon. These novel gene therapy products were developed at the Stanford University School of Medicine and are exclusively licensed to Abeona.
Financial terms:
Latest news:
